Svein Lien appointed ceo of Biotec Pharmacon

Lien has a financial background and extensive experience at technology and diagnostics businesses

Svein Lien has become chief executive of Norwegian pharmaceutical firm Biotec Pharmacon following the resignation of Lars Viksmoen.

Lien has a financial background and extensive experience at technology and diagnostics businesses, most recently as chief executive of Axis-Shield, a diagnostic company listed in London and Oslo.

Following divestment of Immunocorp Animal Health in 2008 and Immunocorp Consumer Health at the end of 2009 Biotec Pharmacon has narrowed its strategic focus to two core business areas: pharmaceutical development and marine biochemicals.

Pharmaceutical development is in the research and development phase, while Biotec Marine Biochemicals specialises in cold-adapted marine enzymes for the molecular biology and diagnostics markets.

You may also like

Ingredients

ArcticZymes receives research grant of US$1.3m

To develop new enzymes for research and diagnostics
Research & Development

Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research

Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development

PSI launches platform to speed up site ID, startup and enrolment in pivotal studies

SYNETIC is designed to speed up site identification, startup and patient enrollment in pivotal clinical trials
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Pharmaceutical

PharmNovo enhances its board ahead of Phase II development

The new board members bring complementary experience in drug development, clinical execution and partnering, supporting the company’s continued progress and dialogue with potential partners
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Research & Development

Baseline Therapuetics launches to advance GLP-1 Phase III Programme in Alcohol Use Disorder

The clinical-stage biotech has launched to progress BT-001, a once-weekly GLP-1 receptor agonist, into FDA-aligned Phase III trials for alcohol use disorder, with studies planned to begin in 2026
Subscribe now